Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 30 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
- SECuRE trial to continue with no modifications to protocol
- Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
- Co-PSMA abstract accepted for oral presentation at EAU
- Positive guidance from the US FDA on Cu-64 SARTATE Phase III
Later from Clarity Pharmaceuticals
- Co-PSMA abstract released
- Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
- SECuRE trial update
- SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET
- Half Yearly Report and Accounts
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals